Abstract:Transforming growth factor-β (TGF-β), an important cytokine that plays a key role in many diseases regulates a wide array of cellular and physiologic processes via several TGF-β-driven signaling cascades, including the SMAD and non-SMAD-driven pathways. However, the detailed mechanisms by which TGF-β induces such diverse responses remain poorly understood. In particular, compared to the SMAD-dependent pathway, SMAD-independent pathways such as the ERK/MAPK pathway, which is critical in cancer progression, are less characterized. Here, we develop an integrated mechanistic model of the TGF-β-triggered ERK activation pathway and its crosstalk with the SMAD pathway, an analysis of which demonstrates how SMAD dynamics can be significantly modulated and regulated by the ERK pathway. In particular, SMAD-mediated transcription can be altered and delayed due to expedited phosphorylation of the linker of SMAD by TGF-β-activated ERK; and enhanced ERK activity, but attenuated SMAD activity, can be achieved simultaneously by fast turnover of TGF-β receptors via lipid-rafts. Also, in silico mutations of the TGF-β pathways reveal that the dynamic characteristics of both SMAD and ERK signaling may change significantly during cancer development. Specifically, normal cells may exhibit enhanced and sustained SMAD signaling with transient ERK activation, whereas cancerous cells may produce elevated and prolonged ERK signaling with enervated SMAD activation. These distinctive differences between normal and cancerous signaling behavior provide clues concerning, and potential explanations for, the seemingly contradictory roles played by TGF-β during cancer progression. We demonstrate how crosstalk among various branch pathways of TGF-β can influence overall cellular behavior. Based on model analysis, we hypothesize that aberrant molecular alterations drive changes in the intensity and duration of SMAD and ERK signaling during cancer progression and ultimately lead to an imbalance between the SMAD and ERK pathways in favor of tumor promotion. Thus, to treat cancer patients with a genetic signature of oncogenic Ras effectively may require at least a combination therapy to restore both the expression of TGF-β receptors and the GTPase activity of Ras.

Pathway sensitivity analysis for detecting pro-proliferation activities of oncogenes and tumor suppressors of epidermal growth factor receptor-extracellular signal-regulated protein kinase pathway at altered protein levels.

Pathway Sensitivity Analysis for Detecting Pro‐proliferation Activities of Oncogenes and Tumor Suppressors of Epidermal Growth Factor Receptor‐extracellular Signal‐regulated Protein Kinase Pathway at Altered Protein Levels

Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival

Cancer Stem Cell, Niche and EGFR Decide Tumor Development and Treatment Response: A Bio-Computational Simulation Study.

Systems-based analysis of responses to stimulation or inhibition of EGF receptor signaling in breast cancer cells

Cross-Scale Sensitivity Analysis of a Non-Small Cell Lung Cancer Model: Linking Molecular Signaling Properties to Cellular Behavior

Pathway-based analysis of breast cancer.

Dynamic Simulation and Analysis of ERK Signal Pathway Activated by Epidermal Growth Factor Receptor

Towards Pathway-Centric Cancer Therapies Via Pharmacogenomic Profiling Analysis of Erk Signalling Pathway

Mathematical Modeling and Inference of Epidermal Growth Factor-Induced Mitogen-Activated Protein Kinase Cell Signaling Pathways

Dynamics and Sensitivity of Signaling Pathways

Modeling the Response of A Tumor-Suppressive Network to Mitogenic and Oncogenic Signals

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

Systems Perturbation Analysis of a Large Scale Signal Transduction Model Reveals Potentially Influential Candidates for Cancer Therapeutics

Progressive Loss of Epidermal Growth Factor Receptor in a Subpopulation of Breast Cancers: Implications in Target-Directed Therapeutics

Simulating EGFR-ERK Signaling Control by Scaffold Proteins KSR and MP1 Reveals Differential Ligand-Sensitivity Co-Regulated by Cbl-CIN85 and Endophilin

The Logic of EGFR/ErbB Signaling: Theoretical Properties and Analysis of High-Throughput Data

Dynamic Analysis of Feedback Loops in Extra-Cellular Signal Regulated Kinase Signal Network

Computational Modeling and Analysis of the TGF-β-induced ERK and SMAD Pathways

Computational modeling of the EGFR network elucidates control mechanisms regulating signal dynamics

[Expression and Activation of MAPK Pathway Signaling Molecules in Human Breast Cancer Cell Lines].